| Literature DB >> 31758914 |
Rami Alzhrani1, Hashem O Alsaab2, Alex Petrovici3, Ketki Bhise3, Kushal Vanamala3, Samaresh Sau3, Matthew J Krinock4, Arun K Iyer5.
Abstract
The delivery of noncoding (nc)RNA to target cancer stem cells and metastatic tumors has shown many positive outcomes, resulting in improved and more efficient treatment strategies. The success of therapeutic RNA depends solely on passing cellular barriers to reach the target site, where it binds to the mRNA of the interest. By 2018, 20 clinical trials had been initiated, most focusing on cancer and diabetes, with some progressing to Phase II clinical trials testing the safety and efficacy of small interfering (si)RNA. Many challenges limit RNA interference (RNAi) and miRNA usage in vivo; therefore, various approaches have been developed to promote ncRNA efficiency and stability. In this review, we focus on targeting the tumor microenvironment (TME) via the modification of delivery systems utilizing nanotechnology-based delivery approaches.Entities:
Year: 2019 PMID： 31758914 PMCID： PMC7200292 DOI： 10.1016/j.drudis.2019.11.006
Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851